Sector News

Perrigo racks up more opposition to Mylan’s now-official hostile bid

September 14, 2015
Life sciences

It’s official: Mylan has taken its Perrigo buyout offer to the Irish company’s shareholders. But plenty of industry-watchers are still opposed to the idea.

The Dublin drugmaker has advised its investors to “take no action” regarding Mylan’s offer, which involves Perrigo shareholders netting $75 in cash and 2.3 Mylan share for each Perrigo share. The company’s board will assess the offer and make an official recommendation within the next 10 days, it said.

Perrigo has been opposed to the tie-up from the outset, and recently, one of its high-profile shareholders–former company vice chairman Mori Arkin–spoke out against it, too.

“Usually, when a good company is acquired, it is for a significant premium. In our case, it’s negligible, if at all,” he told Reuters, predicting that Perrigo’s stock–which currently sits at around $180–would trade at near $190 come early next year.

And they’re not alone in their thinking. Valuation is “currently the key factor that will likely preclude Perrigo shareholders from tendering their shares,” Citi analysts wrote in a note to clients last week, and it’s the implied valuation of Mylan’s bid that is “likely to constitute the primary hurdle to Perrigo shareholder support for the transaction.”

BMO Capital Markets analyst David Maris chimed in Thursday, too, writing to investors that “we believe Perrigo is better off without Mylan” because of Mylan’s too-low offer, skepticism in its ability to squeeze out costs, and its lack of experience in the OTC business that’s Perrigo’s bread and butter.

Regardless, Mylan’s execs are still confident they can get the job done. “The strategic logic behind this combination is abundantly clear,” CEO Heather Bresch said in a statement on Monday, with chairman Robert Coury adding that the company believes “the majority of Perrigo shareholders will support this full and compelling offer.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend